Skip to Content
Merck
  • Design and in vitro evaluation of a novel vaginal drug delivery system based on gelucire.

Design and in vitro evaluation of a novel vaginal drug delivery system based on gelucire.

Current drug delivery (2009-05-20)
M Patel Geeta, M Patel Madhabhai
ABSTRACT

Carbamazepine indicated for the control of epilepsy, undergoes extensive hepatic first-pass metabolism after oral administration. A vaginal dosage form of carbamazepine is not commercially available. Conventional suppository having poor retention in the vaginal tract, as they are removed in a short time by the tract's self-cleansing action, having poor patient compliance. To overcome such problems, delivery system with mucoadhesive polymers polyox WSR N-60K and Ucarflock 302 that prolong drug permanence on the vaginal mucosa were developed. In the present study the suitability of gelucires to formulate vaginal pesseries was investigated. The possible modification of carbamazepine release kinetics by using gelucires blends and hydrophilic additives in the pesseries was evaluated. It was observed that among gelucire grades melting point higher than 37 degrees C, the release rate proved to be highly dependant on HLB value and matrix composition. In most of the formulations carbamazepine release occurred by disintegration and erosion of the matrices which is depending upon the vehicle employed. The aging study revealed that the formulations containing G50/13 and G50/13-G44/14 blends undergo some changes during one year of shelf aging. From the results obtained it can be concluded that different gelucire grades and their blends along with hydrophilic polymer could be successesively used to formulate prolong release carbamazepine pesseries.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Kollisolv® PEG E 400
Sigma-Aldrich
Kollisolv® PEG E 300
Supelco
Polyethylene glycol/Polyethylene oxide ReadyCal Set Mp ~250 -1′100 000, analytical standard
Sigma-Aldrich
Polyethylene glycol/ dimethyl sulfoxide solution, Hybri-Max, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 400
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 1,500
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 4,000
Sigma-Aldrich
Poly(ethylene glycol), average Mn 600, waxy solid (moist)
Sigma-Aldrich
Poly(ethylene glycol), average Mn 3,350, powder
Supelco
Poly(ethylene glycol), analytical standard, for GPC, 40,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 3,350
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 3,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 35,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 2,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, for molecular biology, 1,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 600
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 1,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 300
Supelco
Poly(ethylene glycol), analytical standard, for GPC, 108,000
Sigma-Aldrich
Poly(ethylene glycol), average Mn 20,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 8,000
Sigma-Aldrich
Poly(ethylene glycol), average Mw 1,500
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~4,000,000 (nominal), contains <1000 ppm BHT as inhibitor
Sigma-Aldrich
Poly(ethylene oxide), average Mv 400,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~900,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~8,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~2,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv 200,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~5,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene glycol), average Mn 4,000, platelets